Oncology
Clinical Translational Research
Time-Course Studies of Implanted Rabbit VX2 Liver Tumors to Identify the Appropriate Time for Starting Hepatic Arterial Embolization in Animal ModelsSonoda A.a · Nitta N.a · Nitta-Seko A.a · Ohta S.a · Nagatani Y.a · Mukaisho K.b · Otani H.a · Tsuchiya K.a · Takahashi M.a · Murata K.aDepartments of aRadiology and bPathology, Shiga University of Medical Science, Otsu, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: December 14, 2010
Accepted: April 11, 2011
Published online: June 13, 2011
Issue release date: June 2011
Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 4
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Abstract
Purpose: We followed the 4-week course of implanted VX2 tumors in rabbits and compared MRI and pathological findings to determine the appropriate time for starting therapy in animal liver tumor models. Materials and Methods: We used 18 Japanese white rabbits. The VX2 liver tumor was harvested from one tumor-bearing rabbit and implanted in the liver of the other 17 rabbits. They were then sacrificed at 1 (n = 5), 2 (n = 3), 3 (n = 4), and 4 weeks (n = 5) after implantation and MRI study. Using MRI scans and/or pathological specimens of individual rabbits, we evaluated the tumor survival ratio, the major tumor axes, intrahepatic metastases, and peritoneal dissemination. Results: All tumor transplantations were successful. At 1 week, 56.25% of the implanted tumors were visualized on MRI scans. At 2 weeks or later, all transplanted rabbits were confirmed to be tumor-bearing on MRI scans. At 3 weeks after implantation, the tumor size was similar on MRI scans and in pathological specimens. There were no intra-hepatic metastases or peritoneal disseminations within 2 weeks of tumor transplantation. Conclusion: We suggest that in studies of implanted VX2 models addressing the treatment of solid hepatic tumors, it may be prudent to start hepatic arterial embolization at 2 weeks after implantation.
© 2011 S. Karger AG, Basel
Related Articles:
References
- Morimoto K, Sakaguchi H, Tanaka T, et al: Transarterial chemoembolization using cisplatin powder in a rabbit model of liver cancer. Cardiovasc Intervent Radiol 2008;31:981–985.
- Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL: Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002;62:3909–3913.
- Park HS, Chung JW, Jae HJ, et al: FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model. Korean J Radiol 2007;8:216–224.
- Hong K, Kobeiter H, Georgiades CS, Torbenson MS, Geschwind JF: Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer. J Vasc Interv Radiol 2005;16:1711–1717.
- Ohta S, Nitta N, Sonoda A, et al: Prolonged local persistence of cisplatin-loaded gelatin microspheres and their chemoembolic anti-cancer effect in rabbits. Eur J Radiol 2009;72:534–540.
- Chen JH, Lin YC, Huang YS, et al: Induction of VX2 carcinoma in rabbit liver: comparison of two inoculation methods. Lab Anim 2004;38:79–84.
- DeLeo MJ 3rd, Gounis MJ, Hong B, Ford JC, Wakhloo AK, Bogdanov AA Jr: Carotid artery brain aneurysm model: in vivo molecular enzyme-specific MR imaging of active inflammation in a pilot study. Radiology 2009;252:696–703.
- Keilholz SD, Bozlar U, Fujiwara N, et al: MR diagnosis of a pulmonary embolism: comparison of P792 and Gd-DOTA for first-pass perfusion MRI and contrast-enhanced 3D MRA in a rabbit model. Korean J Radiol 2009;10:447–454.
Article / Publication Details
Received: December 14, 2010
Accepted: April 11, 2011
Published online: June 13, 2011
Issue release date: June 2011
Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 4
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
